세계의 DNA 진단 시장 : 제품 유형별, 기술별, 샘플 유형별, 용도별, 최종 사용자별 - 예측(2025-2030년)

The DNA Diagnostics Market was valued at USD 11.37 billion in 2023, expected to reach USD 12.40 billion in 2024, and is projected to grow at a CAGR of 9.24%, to USD 21.12 billion by 2030.

The DNA Diagnostics market encompasses a diverse array of techniques used to examine genetic material, aimed primarily at detecting genetic disorders, identification, and forensic applications. This field is indispensable in modern medicine and forensics, as it encompasses a range of applications from prenatal diagnostics, infectious disease detection, ancestral heritage exploration, to personalized medicine and pharmaceutical applications. With growing demand for personalized healthcare, the application scope is expanding into predictive and personalized treatment plans, as well as targeted drug development. This market serves varied end-users including healthcare providers, research institutes, and forensic departments, as well as direct-to-consumer services. Key growth factors include the rapidly declining costs of genetic sequencing, technological advancements such as CRISPR and next-generation sequencing, and a rising prevalence of genetic disorders necessitating diagnostic interventions. Moreover, awareness and acceptance of genetic testing among consumers are bolstering market growth. Recently, significant opportunities have emerged in the form of partnerships between biotech companies and healthcare providers to enhance diagnostic capabilities, as well as the integration of AI to streamline data handling processes. However, challenges such as stringent regulatory frameworks, ethical concerns regarding genetic privacy, and the complexity of genetic data interpretation pose limitations to growth. The best avenues for innovation lie in enhancing the accuracy and affordability of DNA testing tools, developing advanced bioinformatics tools for data analysis, and expanding the utility of genetic diagnostics beyond traditional applications. Additionally, creating consumer-friendly platforms to facilitate easy access and interpretation of genetic data could further stimulate market expansion. While the DNA Diagnostics market is poised for robust growth, businesses must navigate regulatory landscapes and data security challenges effectively to harness its full potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving DNA Diagnostics Market

The DNA Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of genetic disorders globally
  • Growing awareness about genetic testing and its associated benefits
  • Rising trend towards personalized medicines
• Market Restraints
  • High cost of DNA diagnostic tests
• Market Opportunities
  • Integration of DNA diagnostics with digital health platforms and apps
  • Ongoing advancements in non-invasive DNA testing methods
• Market Challenges
  • Concerns associated with the accuracy and reliability of some DNA diagnostic tests

Porter's Five Forces: A Strategic Tool for Navigating the DNA Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the DNA Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the DNA Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the DNA Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the DNA Diagnostics Market

A detailed market share analysis in the DNA Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the DNA Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the DNA Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the DNA Diagnostics Market

A strategic analysis of the DNA Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the DNA Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux, Danaher Corporation, DNA Diagnostic A/S, Eurofins, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics, Natera, Inc., Oxford Nanopore Technologies PLC, Promega Corporation, QIAGEN GmbH, Quest Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the DNA Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Instruments/Hardware, Reagents & Consumables, and Software & Services.
• Based on Technology, market is studied across CRISPR Diagnostics, Fluorescence In Situ Hybridization, Microarray Techniques, Next-Generation Sequencing, Polymerase Chain Reaction, and Sanger Sequencing.
• Based on Sample Type, market is studied across Blood Samples, Saliva Samples, and Tissue Samples.
• Based on Application, market is studied across Cancer Diagnostics, Forensic Testing, Genetic Disease Testing, Human Leukocyte Antigen Typing, Infectious Disease Testing, Preimplantation Genetic Diagnosis, Prenatal/Neonatal Diagnostics, and Transplant Diagnostics.
• Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, Diagnostic Laboratories, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genetic disorders globally
    • 5.1.1.2. Growing awareness about genetic testing and its associated benefits
    • 5.1.1.3. Rising trend towards personalized medicines
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of DNA diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of DNA diagnostics with digital health platforms and apps
    • 5.1.3.2. Ongoing advancements in non-invasive DNA testing methods
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with the accuracy and reliability of some DNA diagnostic tests
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type : Increasing preference for software and services in hospitals and clinics for extensive patient data analysis
  • 5.2.2. End User : Rising demand for point-of-care testing solutions and rapid diagnostic kits in hospitals and clinics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. DNA Diagnostics Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments/Hardware
• 6.3. Reagents & Consumables
• 6.4. Software & Services

7. DNA Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. CRISPR Diagnostics
• 7.3. Fluorescence In Situ Hybridization
• 7.4. Microarray Techniques
• 7.5. Next-Generation Sequencing
• 7.6. Polymerase Chain Reaction
• 7.7. Sanger Sequencing

8. DNA Diagnostics Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood Samples
• 8.3. Saliva Samples
• 8.4. Tissue Samples

9. DNA Diagnostics Market, by Application

• 9.1. Introduction
• 9.2. Cancer Diagnostics
• 9.3. Forensic Testing
• 9.4. Genetic Disease Testing
• 9.5. Human Leukocyte Antigen Typing
• 9.6. Infectious Disease Testing
• 9.7. Preimplantation Genetic Diagnosis
• 9.8. Prenatal/Neonatal Diagnostics
• 9.9. Transplant Diagnostics

10. DNA Diagnostics Market, by End User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Contract Research Organizations
• 10.4. Diagnostic Laboratories
• 10.5. Hospitals & Clinics
• 10.6. Pharmaceutical & Biotechnology Companies

11. Americas DNA Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific DNA Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa DNA Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bio-Rad and OncoCyte Join Forces to Revolutionize Transplant Monitoring with Cutting-Edge ddPCR Assay for Accurate Donor-Derived Cell-Free DNA Detection
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Adaptive Biotechnologies
• 3. Agilent Technologies, Inc.
• 4. ARUP Laboratories
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. BioMerieux
• 8. Danaher Corporation
• 9. DNA Diagnostic A/S
• 10. Eurofins
• 11. Exact Sciences Corporation
• 12. F. Hoffmann-La Roche Ltd.
• 13. Hologic, Inc.
• 14. Illumina, Inc.
• 15. Invitae Corporation
• 16. Laboratory Corporation of America Holdings
• 17. Luminex Corporation
• 18. Myriad Genetics
• 19. Natera, Inc.
• 20. Oxford Nanopore Technologies PLC
• 21. Promega Corporation
• 22. QIAGEN GmbH
• 23. Quest Diagnostics
• 24. Siemens Healthineers
• 25. Sysmex Corporation
• 26. Thermo Fisher Scientific Inc.
• 27. Veracyte, Inc.